ENT Department, Hospital Valle del Nalón , Asturias , Spain.
ENT Department, Hospital de Cabueñes , Asturias , Spain.
Hum Vaccin Immunother. 2019;15(9):2150-2153. doi: 10.1080/21645515.2019.1581537. Epub 2019 Apr 17.
Recurrent tonsillitis in adults is a common ENT disease. The current standard treatment is tonsillectomy. However, continuous prophylaxis with antibiotics has been prescribed in order to avoid tonsillectomy. The objective was to evaluate if the bacterial immunotherapy (Bactek MV130) together with the prophylactic antibiotic therapy can produce clinical improvement and to avoid the tonsillectomy. The medical records of 88 patients with recurrent tonsillitis were reviewed. Sixty-six were treated during 3 months with a course of antibiotics and 22 received, in addition to the antibiotics, immunotherapy with Bactek MV130 during this Globally, 53 (60%) patients had clinical improvement and 35 were tonsillectomized. In the The group of patients who received only antibiotic, 35 (53%) avoided tonsillectomy and 31 (47%) did not. In the group that, in addition to antibiotics, were treated with Bactek MV130, 18 patients (82%) experi- enced clinical improvement avoiding tonsillectomy and 4 (18%) didn't improve and the tonsils were surgically removed. The difference between both groups was significant (P = 0.023).he results obtained in this evaluation support this combined treatment as an effective strategy to reduce the need of tonsillectomy.
成人复发性扁桃体炎是一种常见的耳鼻喉科疾病。目前的标准治疗方法是扁桃体切除术。然而，为了避免扁桃体切除术，已经开了连续预防性抗生素治疗。目的是评估细菌免疫疗法（Bactek MV130）联合预防性抗生素治疗是否能产生临床改善并避免扁桃体切除术。
回顾了 88 例复发性扁桃体炎患者的病历。66 例患者在 3 个月内接受了抗生素疗程治疗，22 例患者除了抗生素外，还在这段时间内接受了 Bactek MV130 免疫治疗。全球 53（60%）例患者有临床改善，35 例患者行扁桃体切除术。在仅接受抗生素治疗的患者组中，35（53%）例避免了扁桃体切除术，31（47%）例未避免。在除了抗生素之外还接受 Bactek MV130 治疗的患者组中，18 例（82%）患者经历了临床改善并避免了扁桃体切除术，4 例（18%）患者未改善且进行了扁桃体切除术。两组之间的差异具有统计学意义（P = 0.023）。
这项评估的结果支持这种联合治疗作为减少扁桃体切除术需求的有效策略。
